🏭 This partnership enhances sterile manufacturing capabilities in the U.S.
📈 It gives Recipharm access to Exela’s FDA-accredited facility in North Carolina, boosting production capacity.
💉 They aim to manufacture targeted biopharmaceuticals, including vaccines and biologics.
🤝 Both companies anticipate improved service for U.S. and international pharma customers.
Introduction:
The recent strategic alliance between Recipharm and Exela Pharma Sciences marks a significant advancement in contract development and manufacturing organization (CDMO) capabilities, specifically in sterile pharmaceutical production in the United States.
- Recipharm and Exela Pharma Sciences have formed an exclusive strategic alliance to enhance CDMO sterile manufacturing capabilities in the U.S.
- Exela’s FDA-accredited facility in Lenoir, NC, will provide Recipharm access to advanced sterile injectable manufacturing, including vials and pre-filled syringes.
- This collaboration is expected to expand the production capacity to over 100 million units, focusing on specialized biopharmaceuticals and sterile products such as vaccines.
- Exela’s automated processes, including visual inspection and packaging, will be integrated with Recipharm’s standards to enhance compliance for both U.S. and international markets.
- The partnership will also utilize Recipharm’s analytical and commercial expertise to support the development of complex projects in biopharmaceuticals.
Conclusion:
This strategic alliance not only boosts manufacturing capabilities but also signifies a commitment to high-quality production standards in the biopharmaceutical sector, potentially opening new avenues for collaboration and growth in the U.S. and European markets.
